Neoadjuvant Atezolizumab Plus Chemotherapy Numerically Impro

The addition of atezolizumab to neoadjuvant chemotherapy generated numerical improvements in event-free survival, disease-free survival, and overall survival compared with chemotherapy plus placebo in patients with early-stage triple-negative breast cancer.

Related Keywords

Brazil , United States , American , Merck Serono , Daiichi Sankyo , Roche Genentech , Carlosh Barrios , Breast Cancer Annual Congress , Novartis , Syneos Health , Pfizer , Bristol Myers Squibb , Latin American Cooperative Oncology Group , Amgen , Gilead Sciences , Astrazeneca , Cancer Annual Congress , Aveo Oncology , Esmo Breast Cancer Virtual Meeting , News , Conference , Atezolizumab , Tecentriq , Nct03197935 , Phase 3 Impassion031 Trial ,